期刊文献+

慢性丙型肝炎抗病毒治疗进展 被引量:3

Research progress of antiviral therapy on chronic hepatitis C
原文传递
导出
摘要 近年慢性丙型肝炎抗病毒治疗的标准治疗方案优化和直接抗病毒药物研发均取得突破性进展。本文综述近年国内外相关研究进展以及新药研发趋势。 In recent years, chronic hepatitis C antiviral therapy has achieved some breakthroughs both in standard care optimization and direct-acting antiviral agents. This review describes latest progresses in these two aspects and provides a prospect for new development.
作者 尹伟 李成忠
出处 《世界临床药物》 CAS 2013年第12期705-711,共7页 World Clinical Drug
关键词 慢性丙型肝炎 抗病毒治疗 白介素-28B 直接抗病毒药物 无干扰素治疗 chronic hepatitis C antiviral therapy IL-28B direct-acting antiviral agent interferon free therapy
  • 相关文献

参考文献2

二级参考文献32

  • 1[1]Armstrong GL,Wasley A,Simard EP,McQuillan GM,Kuhnert WL,Alter MJ.The prevalence of hepatitis C virus infection in the United States,1999 through 2002.Ann Intern Med 2006;144:705-714
  • 2[2]Law MG,Dore GJ,Bath N,Thompson S,Crofts N,Dolan K,Giles W,Gow P,Kaldor J,Loveday S,Powell E,Spencer J,Wodak A.Modelling hepatitis C virus incidence,prevalence and long-term sequelae in Australia,2001.Int J Epidemiol 2003;32:717-724
  • 3[3]Shepard CW,Finelli L,Alter MJ.Global epidemiology of hepatitis C virus infection.Lancet Infect Dis 2005;5:558-567
  • 4[4]Fung KT,Fung J,Lai CL,Yuen MF.Etiologies of chronic liver diseases in Hong Kong.Eur J Gastroenterol Hepatol 2007;19:659-664
  • 5[5]Fried MW,Shiffman ML,Reddy KR,Smith C,Marinos G,Goncales FL Jr,Haussinger D,Diago M,Carosi G,Dhumeaux D,Craxi A,Lin A,Hoffman J,Yu J.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.N Engl J Med 2002;347:975-982
  • 6[6]Manns MP,McHutchison JG,Gordon SC,Rustgi VK,Shiffman M,Reindollar R,Goodman ZD,Koury K,Ling M,Albrecht JK.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial.Lancet 2001;358:958-965
  • 7[7]Marcellin P,Heathcote EJ,Craxi A.Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen? J Hepatol 2007;47:580-587
  • 8[8]Pearlman BL,Ehleben C,Saifee S.Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.Hepatology 2007;46:1688-1694
  • 9[9]Shiffman ML,Suter F,Bacon BR,Nelson D,Harley H,Sola R,Shafran SD,Barange K,Lin A,Soman A,Zeuzem S.Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.N Engl J Med 2007;357:124-134
  • 10[10]Conjeevaram HS,Fried MW,Jeffers LJ,Terrault NA,Wiley-Lucas TE,Afdhal N,Brown RS,Belle SH,Hoofnagle JH,Kleiner DE,Howell CD.Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.Gastroenterology 2006;131:470-477

共引文献105

同被引文献35

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部